VALBIOTIS SA

the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes

VALBIOTIS SA VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes 02-Oct-2023 / 17:40 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

 

 

 

Press release

 

 

Valbiotis: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes

• The Phase II/III clinical study REVERSE-IT, carried out with the active substance TOTUM•63, in partnership with Nestlé Health Science, will be presented on October 3, during an oral communication at the congress of the European Association for the Study of Diabetes (EASD) 2023.
• This communication will detail the protocol of the REVERSE-IT study, against early glycemic disorders, as well as the complete characteristics of the population included (636 volunteers), at the beginning of the study.
• After a presentation in the United States last June during the prestigious congress of the American Diabetes Association, the oral communication at the EASD this fall marks the undeniable scientific success of this study on an international scale.

 

La Rochelle, October 02, 2023 (17:40 CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the selection of the Phase II/III clinical study REVERSE-IT for an oral presentation at the annual congress of the European Association for the Study of Diabetes (EASD), which takes place from October 2 to 6, 2023 in Hamburg (Germany). The detailed protocol as well as the complete characteristics of the population included, at the start of the study, will be presented during an oral session scheduled for October 3 from 12:30 p.m. to 1:30 p.m.